Investigational drug · Phase 3
FE 999049
Also called: Rekovelle, Follitropin Delta
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Infertility, Female.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
13
Any phase or sponsor naming "FE 999049"
First trial start
2024
Mar 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FE 999049", any sponsor or status.
Conditions studied
As listed on its trial records.
- Infertility, Female
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "FE 999049" as an intervention, largest first.
- Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1Pivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT01956110 · 1,329 participants · Start Oct 2013 · Primary completion May 2015
Drug: Follitropin Delta (FE 999049); Follitropin Alfa (GONAL-F) · For: Infertility
Sites: Brussels, Belgium; Porto Alegre, Brazil; Burnaby, Canada · 13 sites in all
- Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian WomenPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT03296527 · 1,011 participants · Start Dec 1, 2017 · Primary completion Jan 3, 2020
Drug: Follitropin alfa; Follitropin delta · For: Controlled Ovarian Simulation
Sites: Beijing, China; Chengdu, China; Guangzhou, China · 26 sites in all
- Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)Pivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT03738618 · 588 participants · Start Oct 29, 2018 · Primary completion Dec 21, 2020
Drug: Follitropin delta; Placebo · For: Infertility, Female
Sites: Tempe, Arizona; Encino, California; Farmington, Connecticut · 24 sites in all
- Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)Pivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT03740737 · 579 participants · Start Oct 26, 2018 · Primary completion Nov 11, 2020
Drug: Follitropin delta · For: Infertility
Sites: Tempe, Arizona; Encino, California; Farmington, Connecticut · 23 sites in all
- Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2Pivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT01956123 · 513 participants · Start Mar 26, 2014 · Primary completion May 2015
Drug: Follitropin Delta (FE 999049); Follitropin Alfa (GONAL-F) · For: Infertility
Sites: Brussels, Belgium; Porto Alegre, Brazil; Burnaby, Canada · 13 sites in all
- Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)Pivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT03809429 · 437 participants · Start Apr 29, 2019 · Primary completion Feb 16, 2022
Drug: FE 999049 + GnRH agonist (GONAPEPTYL); FE 999049 + GnRH antagonist (CETROTIDE) · For: Infertility, Female
Sites: Dobl, Austria; Linz, Austria; Vienna, Austria · 16 sites in all
- Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese WomenPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT03228680 · 373 participants · Start Jul 29, 2017 · Primary completion Jun 10, 2019
Drug: Follitropin delta; Follitropin beta · For: Infertility
Sites: Anjo, Japan; Chiba, Japan; Maebashi, Japan · 17 sites in all
Ferring PharmaceuticalsIndustry
NCT06173869 · 301 participants · Start Mar 29, 2024 · Primary completion May 31, 2025
Drug: FE 999049; GONAL-F · For: Infertility, Female
Sites: Shushan, China; Yuzhong, China; Guangzhou, China · 11 sites in all
- A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI TreatmentPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT01426386 · 265 participants · Start Sep 2011 · Primary completion Apr 2012
Drug: FE 999049; Gonal - F · For: Infertility
Sites: Brussels, Belgium; Ghent, Belgium; Prague, Czechia · 8 sites in all
- Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian WomenPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT04773353 · 220 participants · Start Dec 3, 2021 · Primary completion Dec 12, 2023
Drug: Follitropin Delta (FE 999049); Follitropin Alfa (GONAL-F) · For: Infertility
Sites: Ahmedabad, India; Anand, India; Nashik, India · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Follitropin delta versus human menopausal gonadotropin in progestin protocol cycles: a retrospective cohort study using inverse probability of treatment weighting.
Fujii T, Iwami N, Takimoto K, et al. · Eur J Obstet Gynecol Reprod Biol 2026
- Preparations of recombinant follicle-stimulating hormone (FSH) alfa and delta induce different intracellular signals in vitro.
Lazzaretti C, Mercanile G, Perri C, et al. · Mol Cell Endocrinol 2026
- Comparative outcomes of conventional follitropin delta 15ߕµg/day versus follitropin alfa 225ߕIU/day for ovarian stimulation: results from an exploratory post hoc analysis of Spanish participants from the ADAPT-1 randomized controlled trial.
García Sánchez M, Bernabeu A, Hernández Cesteros A, et al. · Front Reprod Health 2026
- Patterns of Use of Follitropin Delta in Brazilian Assisted Reproduction: Results of the Multicenter PURO Real World Study.
Dias Junior JA, Antunes RA, Borges E, et al. · JBRA Assist Reprod 2026
- Efficacy of follitropin delta in potential low responders: a pooled analysis of individual patient data from five randomized controlled trials.
Lobo R, Falahati A, Jepsen IE, et al. · Front Endocrinol (Lausanne) 2026
- Restoration of spermatogenesis in a male with prolactinoma-induced hypogonadotropic hypogonadism using follitropin delta and recombinant choriogonadotropin alfa: a case report.
Adel Domínguez MA, Cardona Maya WD, Mora Topete A · J Assist Reprod Genet 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.